Resistance to HER2 targeted therapies presents a major clinical problem. Although preclinical studies have identified a number of possible mechanisms clinical validation has been difficult. This most likely reflects the reliance on cell line models that do not recapitulate the complexity and heterogeneity seen in human tumours. Here we show the utility of a genetically engineered mouse model of HER2 driven breast cancer (MMTV-NIC) to define mechanisms of resistance to the pan-HER family inhibitor AZD8931. Genetic manipulation of MMTV-NIC mice demonstrated that loss of PTEN conferred de novo resistance to AZD8931, while a tumour fragment transplantation model was established to assess mechanisms of acquired resistance. Using this approach 50% of tumours developed resistance to AZD8931. Analysis of the resistant tumours showed two distinct patterns of resistance: tumours in which reduced membranous HER2 expression was associated with an epithelial-to-mesenchymal transition (EMT) and resistant tumours that retained HER2 expression and an epithelial morphology. The plasticity of the EMT phenotype was demonstrated upon re-implantation of resistant tumours that then showed a mixed epithelial and mesenchymal phenotype. Further AZD8931 treatment resulted in the generation of secondary resistant tumours that again had either undergone EMT or had retained their original epithelial morphology. The data provide a strong rationale for basing therapeutic decisions on the biology of the individual resistant tumour, which may be very different from that of the primary tumour and will be specific to individual patients.
Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer
Current address AstraZeneca Innovative Medicines & Early Development, Darwin Building, Cambridge Science Park, Cambridge, CB4 0FZ
Currently Viewing Accepted Manuscript - Newer Version Available
Helen Creedon, Lucy A Balderstone, Morwenna Muir, Jozef Balla, Laura Gomez-Cuadrado, Natasha Tracey, Joseph Loane, Teresa Klinowska, William J Muller, Valerie G Brunton; Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer. Dis Model Mech 2015; dmm.023143. doi: https://doi.org/10.1242/dmm.023143
Download citation file:
Advertisement
Valuing peer review at Disease Models & Mechanisms
We would like to thank our peer reviewers who contributed their time and expertise in 2023. In her latest Editorial, Editor-in-Chief Liz Patton has outlined why we continue to value our peer reviewers dedication.
Subject collection: Building advocacy into research
DMM’s new series - Building advocacy into research - features interviews, ‘The Patient’s Voice’, with patients and advocates for a range of disease types, with the aim of supporting the highest quality research for the benefit of all patients affected by disease.
Travelling Fellowships for early-career researchers
DMM and its sister journals offer Travelling Fellowships of up to £3,000 to graduate students and post-doctoral researchers wishing to make collaborative visits to other laboratories. Find out more about our Travelling Fellowships and read stories from previous grant recipients.
Read & Publish Open Access publishing: what authors say
We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
The Forest of Biologists
Our Publisher Claire Moulton recently visited the two Woodland Trust UK sites where we are planting new native trees for published Research and Review papers and protecting ancient woodland on behalf of our peer reviewers.
Other journals from
The Company of Biologists